meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
mHCC - 1st line (L1) 4
mHCC - 2nd line (L2) 2
lung cancer : non small cell (NSCLC) 5

immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus lenvatinib
sintilimab based treatment
sintilimab

versus all
vs non active control
vs placebo
vs VEGF(R) inhibitor
vs lenvatinib
vs sorafenib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
P2 : SHR-1210-II/III-HCC, 2020	randomized controlled trial			Qin Lancet Oncol 2020; 21:571-580 10.1016/S1470-2045(20)30011-5

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -